Orthopedic oncology is a minor subspecialty of orthopaedics. Orthopedic oncology is a medical condition caused by the growth of benign and malignant tumours in bones and connective soft tissues. It also includes the diagnosis and treatment of patients with skeleton-based metastatic carcinoma. Bone and soft tissue tumours are uncommon and may necessitate reconstructive surgery.
Soft tissue sarcomas occur more frequently than bone sarcomas. The American Cancer Society predicts 3,300 new cases of bone and joint cancer and 12,310 new cases of soft tissue sarcomas in 2016.
Bone cancers are classified into three types: osteosarcoma, which occurs most frequently in the growing ends of long bones, chondrosarcoma, which occurs in the metaphysis, and Ewing’s sarcoma. Malignant bone tumours, also known as chondrosarcoma, are more common in adults than other types of cancer and remain a difficult tumour to diagnose and treat.
Chemotherapy and radiotherapy are no longer the preferred treatment options for this type of tumour, as clinical studies show no significant improvements in patient survival rates. As a result, in the case of chondrosarcoma, adequate surgical resection is the mainstay of treatment.
According to the American Cancer Society, chondrosarcomas are more common in adults, accounting for 40% of cases, while patients under the age of 20 account for less than 5% of cases.
In the case of osteoid osteoma, a benign bone tumour caused by osteoblasts, radiofrequency ablation has become the standard and most preferred treatment option. However, research shows that it has a broader application in the palliative treatment of patients with painful bone metastasis.
The ability to perform less invasive procedures frequently allows for more efficient, painless, and cost-effective patient care. Furthermore, for patients with metastatic disease, minimally invasive techniques such as kyphoplasty, vertebroplasty, and acetabuloplasty may provide an alternative to major reconstructive surgery.
Global Orthopedic Oncology Market: Drivers & Restraints
A rapidly aging population with an increased risk of developing cancer is one of the factors driving the global orthopedic oncology market. Patients who have previously received high-dose external radiation therapy or anti-cancer drug treatment are at a higher risk of developing osteosarcoma.
However, a small number of bone cancers are caused by hereditary bone defects, and people who have metal implants, which are sometimes used to repair fractures, are more likely to develop osteosarcoma. Adults with hereditary disorders such as retinoblastoma, tuberous sclerosis, Werner syndrome, and others are more likely to develop soft tissue sarcoma.
High treatment costs for musculoskeletal oncology diseases, as well as a lack of awareness about effective treatment therapies, are some of the factors that will limit market growth in the near future.
Global Orthopedic Oncology Market: OverviewThe rising prevalence of musculoskeletal disorders is expected to fuel demand for effective treatment therapies for various cancers associated with bones and soft tissues. Over the forecasted period, the orthopaedic oncology market is expected to grow at a healthy rate due to rising cancer prevalence.
Global Orthopedic Oncology Market: Region-wise OutlookThe thrombophilia treatment market is divided into seven key regions based on region presence: North America, Latin America, Eastern Europe, Western Europe, and Asia Pacific excluding Japan, Japan, the Middle East, and Africa. Because of the rising prevalence of cancer and musculoskeletal disorders, the global market for orthopaedic oncology is expected to be stronger in North America and Europe.
Because of its rapidly ageing population and rising cancer incidence, Asia Pacific represents a massive growth opportunity for the orthopaedic oncology market. Furthermore, macroeconomic factors such as FDA approvals are expected to boost device adoption in developed countries.
Global Orthopedic Oncology Market: Key Players Stryker Corporation, Accentus Inc., Roche Diagnostics, Amgen Inc., Novartis AG, Biogen Idec, GlaxoSmithKline, Sanofi S.A., and Pfizer Inc. are some of the key market players in the orthopaedic oncology market.
The research report provides an in-depth analysis of the market and includes thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also includes projections based on an appropriate set of assumptions and methodologies. The research report categorises analysis and information into market segments, geographies, types, technology, and applications.
Global Orthopedic Oncology Market: SegmentationOrthopedic Oncology marketis segmented by treatment, by end user and geography:
- Limb Salvage Surgery
- Reconstructive Surgery
- Radiation Therapy
- Targeted Therapy
By End User
- Multispecialty Hospitals
- Cancer Research Institutes